In recent decades, billions of dollars have gone towards programs aimed at curbing obesity in the U.S., yet the prevalence of obesity remains high. Weight management drugs like Ozempic and Wegovy have come to public awareness recently, though these drugs are often expensive and hard to access, leaving patients to receive the industry's traditional approach to weight management. But are these approaches even helpful?

In this episode, host Rachel Woods invites health equity expert Darby Sullivan and pharmacy expert Chloe Bakst to discuss how the healthcare industry thinks about weight management, why the current approaches may be doing more harm than good, and how healthcare leaders need to think differently about treating obesity and weight.

Ask us a question and hear it on the pod! Email us at podcasts@advisory.com, visit ask.advisory.com, or leave a voicemail at radioadvisory.advisory.com.

Links:

• Ep. 159: Ozempic, Wegovy, and our questions on weight management drugs
• 3 missteps in our approach to treating obesity (and 5 ways to fix it)
• The 5 biggest weight management drug questions (and our answers)
• What the headlines get wrong about weight-management medications

Learn about Advisory Board Sponsorship at advisory.com/sponsorship

A transcript of this episode as well as more information and resources can be found on radioadvisory.advisory.com.